指南与共识复苏、休克与脓毒症创伤与烧伤

平民(院前)创伤救治中复苏性主动脉腔内球囊阻断的共识:一项德尔菲研究

Consensus on resuscitative endovascular balloon occlusion of the aorta in civilian (prehospital) trauma care: A Delphi study.
指南 / 共识 · J Trauma Acute Care Surg · 2024-01-16
一句话结论国际专家小组共识:在人员经过充分培训并建立流程的前提下,REBOA可用于平民院前环境对不可压迫性躯干出血的临时控制;专家组建议启动一项随机临床试验来研究院前REBOA用于不可压迫性躯干出血。

本研究为一项德尔菲研究,基于近期文献回顾进行三轮问卷调查,邀请不同医学专业、背景和工作环境的REBOA专家组成国际专家组。共识标准为:至少75%的小组成员回答某一问题,且至少75%(阳性)或少于25%(阴性)的回答者对该问题达成一致。专家组就潜在(禁忌)适应证、患者选择的生理阈值、超声的使用以及早期股动脉入路和院前REBOA的实践与技术方面达成了共识。结论认为,在人员经过充分培训并建立流程的前提下,REBOA可用于平民院前环境对不可压迫性躯干出血的临时控制;专家组建议启动一项随机临床试验来研究院前REBOA用于不可压迫性躯干出血。证据等级为治疗/照护管理;Level V。

要点

  • 国际专家小组共识:REBOA可用于平民院前环境对不可压迫性躯干出血的临时控制,前提是人员经过充分培训并建立流程。
  • 专家组就院前REBOA和早期股动脉入路的潜在(禁忌)适应证、生理阈值及实践方面达成共识。
  • 共识标准为至少75%的小组成员回答某一问题,且至少75%(阳性)或少于25%(阴性)的回答者达成一致。
  • 专家组建议启动一项随机临床试验,研究院前REBOA用于不可压迫性躯干出血。
  • 证据等级:治疗/照护管理;Level V。

适用人群与场景

  • 平民院前创伤与医疗急救环境中,可能受益于早期REBOA部署的、死亡率高的小部分人群。
  • 目标情况包括不可压迫性躯干出血和院外心脏骤停,以及多种院内环境。

处置流程与药物剂量

  • 在人员经过充分培训并建立流程的前提下,REBOA可用于平民院前环境对不可压迫性躯干出血的临时控制。
  • 专家组就早期股动脉入路和院前REBOA的实践与技术方面达成了共识。

研究设计与关键结果

  • 本研究为德尔菲研究,基于近期文献回顾进行三轮问卷调查,邀请不同医学专业、背景和工作环境的REBOA专家组成国际专家组。
  • 共识标准为至少75%的小组成员回答某一问题,且至少75%(阳性)或少于25%(阴性)的回答者对该问题达成一致。
  • 专家组就潜在(禁忌)适应证、患者选择的生理阈值、超声的使用以及早期股动脉入路和院前REBOA的实践与技术方面达成了共识。
  • 专家组建议启动一项随机临床试验,研究院前REBOA用于不可压迫性躯干出血。

证据类型、等级与局限

  • 证据类型:德尔菲研究(基于文献回顾的三轮问卷调查)。
  • 证据等级:治疗/照护管理;Level V。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 在人员经过充分培训并建立流程的前提下,REBOA可用于平民院前环境对不可压迫性躯干出血的临时控制(专家组共识)。
  • 专家组建议启动一项随机临床试验,研究院前REBOA用于不可压迫性躯干出血(作者建议)。

指南或共识出处

  • 指南/共识名称:平民(院前)创伤救治中复苏性主动脉腔内球囊阻断的共识:一项德尔菲研究(Consensus on resuscitative endovascular balloon occlusion of the aorta in civilian (prehospital) trauma care: A Delphi study)。
  • 发布机构:J Trauma Acute Care Surg。
  • 年份:原文未写明

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Resuscitative endovascular balloon occlusion of the aorta (REBOA) could prevent lethal exsanguination and support cardiopulmonary resuscitation. In prehospital trauma and medical emergency settings, a small population with high mortality rates could potentially benefit from early REBOA deployment. However, its use in these situations remains highly disputed. Since publication of the first Delphi study on REBOA, in which consensus was not reached on all addressed topics, new literature has emerged. The aim of this study was to establish consensus on the use and implementation of REBOA in civilian prehospital settings for noncompressible truncal hemorrhage and out-of-hospital cardiac arrest as well as for various in-hospital settings.

METHODS: A Delphi study consisting of three rounds of questionnaires was conducted based on a review of recent literature. REBOA experts with different medical specialties, backgrounds, and work environments were invited for the international panel. Consensus was reached when a minimum of 75% of panelists responded to a question and at least 75% (positive) or less than 25% (negative) of these respondents agreed on the questioned subject.

RESULTS: Panel members reached consensus on potential (contra)indications, physiological thresholds for patient selection, the use of ultrasound and practical, and technical aspects for early femoral artery access and prehospital REBOA.

CONCLUSION: The international expert panel agreed that REBOA can be used in civilian prehospital settings for temporary control of noncompressible truncal hemorrhage, provided that personnel are properly trained and protocols are established. For prehospital REBOA and early femoral artery access, consensus was reached on (contra)indications, physiological thresholds and practical aspects. The panel recommends the initiation of a randomized clinical trial investigating the use of prehospital REBOA for noncompressible truncal hemorrhage.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level V.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. van de Voort JC, Kessel B, Borger van der Burg BLS, et al. Consensus on resuscitative endovascular balloon occlusion of the aorta in civilian (prehospital) trauma care: A Delphi study. J Trauma Acute Care Surg. 2024. PMID: 38227678. doi:10.1097/TA.0000000000004238

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。